Health Secretary highlights the need for capacity building programmes for Medical Officers to tackle Non Communicable Diseases at the primary level
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable
European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
5C Network’s groundbreaking platform aims to bring together diagnostic facilities and healthcare aggregators on a single platform to deliver an unparalleled patient experience
Testing supporting allergy diagnosis now accessible to more people in more communities
The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
Subscribe To Our Newsletter & Stay Updated
